An isotope dilution-liquid chromatography-tandem mass spectrometry (ID-LC-MS/MS)-based candidate reference measurement procedure (RMP) for the quantification of lamotrigine in human serum and plasma
Clinical Chemistry and Laboratory Medicine (CCLM) · 2023
DOI: 10.1515/cclm-2022-0997 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Chemistry and Laboratory Medicine (CCLM), 2023. Verfasst von Linda Salzmann und 10 weiteren Autor:innen. Beteiligte Einrichtung: Dr. Risch Ostschweiz AG, Buchs, Switzerland. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry, Anticonvulsants. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
We developed an isotope dilution (ID)-liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based candidate reference measurement procedure (RMP) for lamotrigine in human serum and plasma, using quantitative nuclear magnetic resonance-characterized reference standards to ensure traceability to the International System of Units.
Methods
A sample preparation protocol based on protein precipitation combined with LC-MS/MS analysis using a C18 column for chromatographic separation was established for the quantification of lamotrigine in human serum and plasma. Assay validation was performed according to current guidelines. Spiked serum and plasma samples were used to assess selectivity and specificity; a post-column infusion experiment and comparison of standard line slopes were performed to ascertain possible matrix effects. Precision and accuracy were determined in a 5 days validation experiment. Measurement uncertainty was determined per the Guide to the Expression of Uncertainty in Measurement.
Results
The method allowed the quantification of lamotrigine in serum and plasma in a range of 0.600–24.0 μg/mL without any observable matrix effects. The relative mean bias (n=6) ranged from 1.7 to 3.7%; intermediate precision, including variances in between-day, -calibration, and -injection, was ≤2.4%, independent of the level and matrix. Total measurement uncertainty for a single measurement was ≤2.6%; expanded uncertainty was ≤5.2% (coverage factor k=2).
Conclusions
This candidate RMP based on ID-LC-MS/MS provides a traceable and reliable platform for the standardization of routine assays and the evaluation of clinical samples.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dr. Risch Ostschweiz AG, Buchs, Switzerland.
- Roche Diagnostics GmbH, Penzberg, Germany.
- Chrestos Concept GmbH & Co. KG, Essen, Germany.
ORCID-Profile: Lorenz Risch
Zitieren
APA
Salzmann, L., Spescha, T., Singh, N., Schierscher, T., Bachmann, M., Bauland, F., Geistanger, A., Risch, L., Geletneky, C., Seger, C., & Taibon, J. (2023). An isotope dilution-liquid chromatography-tandem mass spectrometry (ID-LC-MS/MS)-based candidate reference measurement procedure (RMP) for the quantification of lamotrigine in human serum and plasma. Clinical Chemistry and Laboratory Medicine (CCLM). https://doi.org/10.1515/cclm-2022-0997
Vancouver
Salzmann L, Spescha T, Singh N, Schierscher T, Bachmann M, Bauland F, et al. An isotope dilution-liquid chromatography-tandem mass spectrometry (ID-LC-MS/MS)-based candidate reference measurement procedure (RMP) for the quantification of lamotrigine in human serum and plasma. Clinical Chemistry and Laboratory Medicine (CCLM). 2023. doi:10.1515/cclm-2022-0997
BibTeX
@article{Salzmann2023,
author = {Salzmann, Linda and Spescha, Tino and Singh, Neeraj and Schierscher, Tobias and Bachmann, Martina and Bauland, Friederike and Geistanger, Andrea and Risch, Lorenz and Geletneky, Christian and Seger, Christoph and Taibon, Judith},
title = {An isotope dilution-liquid chromatography-tandem mass spectrometry (ID-LC-MS/MS)-based candidate reference measurement procedure (RMP) for the quantification of lamotrigine in human serum and plasma},
journal = {Clinical Chemistry and Laboratory Medicine (CCLM)},
year = {2023},
doi = {10.1515/cclm-2022-0997}
}
EUVIMED